Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study.

Signal Transduct Target Ther · 2021 · PMC8558340 · PMID 34719670

Europe PMC DOI

hedged sentence

0.2700

closest p · 5.4× alpha

0.2700

boldest claim

The sentences

did not reach statistical significancep = 0.27not close (p > 0.1)

Among the patients who achieved PR, the number of patients who had ctDNA clearance was numerically higher than those who remained ctDNA positive; however, it did not reach statistical significance (72.7% (40/55) vs 27.3% (15/55); p = 0.27).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.